High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Ychou M, Raoul JL, Desseigne F, Borel C, Caroli-Bosc FX, Jacob JH, Seitz JF, Kramar A, Hua A, Lefebvre P, Couteau C, Merrouche Y.
Ychou M, et al. Among authors: borel c.
Cancer Chemother Pharmacol. 2002 Nov;50(5):383-91. doi: 10.1007/s00280-002-0506-7. Epub 2002 Sep 26.
Cancer Chemother Pharmacol. 2002.
PMID: 12439596
Clinical Trial.